Trial intelligence / Profile preview

Phase 3 randomized study of oral azacitidine versus investigator's choice therapy in relapsed or refractory angioimmunoblastic T-cell lymphoma

jRCT2080224055Phase 3Completed

Sponsor

Bristol Myers Squibb

Start

Sep 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules